|
1.1 Biologie - Gènes
|
|
|
|
2. Etiologie
|
|
|
|
2.10 Etiologie - Alcool
|
|
|
|
3.1.1 Prévention - Tabac - e-cigs
|
|
|
|
3.4.1 Chimioprévention - aspirine
|
|
|
|
4. Dépistage, diagnostic et pronostic
|
|
|
|
|
4.12 Biopsies liquides
|
|
|
New blood test detects early stage pancreatic cancer [Lund University]
|
|
|
|
|
|
Pancreatic
cancer is currently very difficult to detect while it is still
resectable. A new blood test developed by researchers at Lund University
in Sweden, Herlev Hospital, Knight Cancer Center and Immunovia AB, can
detect pancreatic cancer in the very earliest stages of the disease. The
results have been published in the Journal of Clinical Oncology.
|
|
|
|
|
|
|
4.2 Dép., diag. & prono. - Génome
|
|
|
|
The BRCA1 Gene: Trouble, Quantified [In the Pipeline]
|
|
|
|
|
|
The
next step, clearly, is to extend this approach to more of the BRCA1
sequence, and to try applying it to other targets. The first one should
be pretty straightforward, but the second will depend on careful choice
of the cell assay.
|
|
|
|
|
|
|
5.12.2 Immunothérapies - CAR-T, thérapies cellulaires
|
|
|
London biotherapeutics powerhouse launched by Cancer Research UK [Cancer Research UK]
|
|
|
|
|
|
We
need to understand why some patients respond to these new treatments
while others don’t, and how to identify which patients might experience
harmful side effects. Most importantly, we need to optimise their
activity to offer more patients access to these therapies who may
benefit. With this substantial new funding and world leading expertise,
the Cancer Research UK City of London Centre is especially well placed
to deliver on these promises.
|
|
|
|
|
|
|
|
5.2 Pharma
|
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
|
6.1 Observation
|
|
|
|
6.11 Patients
|
|
|
|
6.12 Ethique
|
|
|
|
|
6.3 Associations/Fondations
|
|
|
|
6.5 Médecines alternatives/complémentaires
|
|
|
|
6.6 Publications
|
|
|
How Traditional Publishing Works [The Scholarly Kitchen]
|
|
|
|
|
|
For
traditional publishers editorial quality is the means to effect a sale,
whereas for an OA service, that quality is epiphenomenal. OA is built
upon the assumption of abundance, not of finite resources; over time the
form of the publications of OA and traditional publishing will pull
further and further apart.
|
|
|
|
|
|
|
6.7.1 IA/bioinformatique
|
|
|
|
6.7.2 Applis
|
|
|
|
6.9 Controverses
|
|
|
The Cochrane Collaboration—what crisis? [BMJ Blogs]
|
|
|
|
|
|
Maintaining—and
funding—the “view from nowhere” requires delicate navigation of tricky
political spaces and sometimes accepting hard-won compromises. Board
members are presumably expected not to spit in the soup (especially when
using Cochrane letterhead).
|
|
|
|
|
|
|
Mass resignation guts board of prestigious Cochrane Collaboration [Nature]
|
|
|
|
|
|
David
Hammerstein Mintz, a board member who stepped down in protest, said
some members thought that Gøtzsche’s critical views of Cochrane were
“disloyal”. “It might have been a headache, but the harm done by
expelling Peter is much greater than any inconvenience caused by
scientific debate,” he says.
|
|
|
|
|
|
|